treatment resistant depression trd market size
DelveInsight's "Treatment-Resistant Depression (TRD)—market-2028" report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Treatment-Resistant Depression in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Treatment-Resistant Depression from 2017 to 2028 segmented by seven major markets.
The phenomenon of Treatment-resistant depression (TRD) is described as the occurrence of an inadequate response after adequate treatment with antidepressant agents (in terms of dose, duration, and adherence). It has been broadly defined in the context of major depression disorder (MDD) (unipolar ajor depression), but alternative definitions for bipolar depression have also been suggested.
The European Union's Committee for Human Proprietary Medicinal Products (CHMP) defines TRD as follows: 'A patient is considered therapy-resistant (TRD) when consecutive treatments with two different antidepressant products, used for a sufficient length of time at an adequate dose with adequate affirmation of treatment adherence, fail to induce a clinically meaningful improvement.'
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017-2028
Treatment-Resistant Depression - Disease Understanding and Treatment Algorithm
The classification of TRD in stages has been recently proposed where increasing resistance is equated with an increased failure to respond to antidepressant strategies. The rationale behind this approach is the clinical impression that the greater the degree of treatment resistance, the lower the probability of response to any new treatment. This perspective has yet to be empirically tested, and it is important to keep in mind that all classifications of TRD are not diagnoses per se.
A relatively wide variety of treatment options for unipolar TRD are available, whilst the evidence is very scanty for bipolar TRD. TRD is associated with poor clinical, functional, and social outcomes. Several novel therapeutic options are currently being investigated as promising alternatives, targeting the neurotransmitter system outside of the standard monoamine hypothesis.
Treatment-Resistant Depression Epidemiology
The Treatment-Resistant Depression epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent cases, Gender-Specific Prevalence, and Age-Specific Prevalence) scenario of Treatment-Resistant Depression in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.
According to DelveInsight, the total prevalent cases of Treatment-Resistant Depression (TRD) in the 7MM was found to be 8,339,329 in 2017. The prevalence of Treatment-Resistant Depression in the 7MM is expected to increase during the study period of 2017-2028.
Treatment-Resistant Depression Drug Chapters
This segment of the Treatment-Resistant Depression report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, the therapeutic market size of TRD in the US is mainly accounted for the management options consisting of pharmacologic treatment options and non-pharmacological therapies.
Pharmacologic treatment options include switching, combination and potentiation strategy among the commonly used antidepressant drugs. Most of the available antidepressants, such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), ?2-antagonists, Agomelatine, Tianeptine are used to treat TRD.
Spravato and Symbyax are the two FDA approved drugs specifically for the treatment of TRD. Other pharmacologic alternatives are also considered for those having an antidepressant action, such as in monotherapy: Bupropion, selective and reversible MAOIs, Quetiapine and in combination with a first-line antidepressant: Lithium, Lamotrigine and second-generation antipsychotics.
Non-pharmacological therapies include electroconvulsive therapy (ECT), Repetitive transcranial magnetic stimulation (rTMS), and Vagus nerve stimulation (VNS). Along with this, two alternative forms of psychotherapy involve majorly cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT).
Detailed chapters of current therapies, such as Symbyax (olanzapine and fluoxetine hydrochloride) (Eli Lilly and Company), Spravato (Esketamine) (Johnson and Johnson), and emerging therapies, such as ALKS 5461 (Alkermes), AXS-05 (Axsome Therapeutics), Cariprazine (Allergan/Gedeon Richter's), Pimavanserin (Acadia Pharmaceuticals), Seltorexant (JandJ/ Minerva Neurosciences), Esketamine DPI (Celon Pharma), REL-1017 (Relmada Therapeutics), AV-101 (Vistagen therapeutics), and others have also been provided in the report.
Treatment-Resistant Depression Market Outlook
The Treatment-Resistant Depression market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
According to DelveInsight, the market for Treatment-Resistant Depression in 7MM was found to be approximately USD 3,698.34 Million in 2017.
Treatment-Resistant Depression market size in the United States accounted for 71% of the total market in 2017. The US led the market in 2017, followed by the EU5 and Japan, respectively. Due to the high prevalence of this disease in the region, the Treatment-Resistant Depression treatment market in the US is expected to dominate the market during the forecast period (2019-2028).
Treatment-Resistant Depression Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.
The dynamics of Treatment-Resistant Depression market is anticipated to change in the coming years owing to the expected launch of emerging therapies, such as, AXS-05 (Axsome Therapeutics), ALKS-5461 (Alkermes), Esketamine Nasal Spray (Janssen Pharmaceuticals), Cariprazine (Allergan/ Gedeon Richter), Seltorexant (Minerva Neurosciences), Rapastinel (Naurex), Seltorexant (Minerva Neurosciences), Pimavanserin (Acadia Pharmaceuticals), and AV-101 (VistaGen Therapeutics), and others in the Treatment-Resistant Depression market by 2028.
Treatment-Resistant Depression Report Insights
• Patient Population of Treatment-Resistant Depression
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Treatment-Resistant Depression Report Key Strengths
• 10-Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Treatment-Resistant Depression Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Treatment-Resistant Depression market
• Organize sales and marketing efforts by identifying the best opportunities for Treatment-Resistant Depression market
• To understand the future market competition in the Treatment-Resistant Depression market
